Latest News and Press Releases

–Generated $29.4 Million in Cash Flow from Operations––Reaffirmed Full Year 2026 Net Revenue and Adjusted EBITDA Guidance– SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Turtle Beach Corporation...

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing...

Issued on behalf of Lake Victoria Gold Ltd. Sterilization drilling commences mid-May ahead of construction at the fully-permitted Imwelo Gold Project in Tanzania. Supported by committed and...

FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and...

Acorn (ACFN) Reports Q1 Revenue of $2.2M with Steady Growth in High Margin, Recurring Remote Monitoring and Control Revenue; Investor Call Today at 11am ET

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared...

First Quarter Total Revenue of $86.8 Million, an Increase of 5% Versus Prior Year. GAAP Net Income of $3.7 Million Versus Net Loss in Prior Year Period.

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and...

Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026  Zipalertinib NDA for...

Establishes domestic platform in advanced graphite, addressing a multi-billion-dollar end market underpinned by U.S. supply-chain reshoring and next-generation nuclear deployment TOMI Environmental...